Innovation and Alfasigma Ink Pact to Develop and Commercialize Brilacidin for Types of IBD

Innovation and Alfasigma Ink Pact to Develop and Commercialize Brilacidin for Types of IBD
Innovation Pharmaceuticals now has a global licensing agreement with Alfasigma for the development and commercialization of the therapy  Brilacidin for treating ulcerative proctitis/ulcerative proctosigmoiditis (UP/UPS), types of inflammatory bowel disease (IBD). Innovation’s lead candidate, Brilacidin is a synthetic small molecule that structurally resembles some of the proteins the body produces to fend off bacteria and other microbial invaders. That’s why it’s being studied as an antibiotic. But, Brilacidin also has immunomodulatory properties — meaning it can lower inflammation and even promote wound-healing — making it a prospective therapy for UP/UPS, a type of ulcerative colitis. Data from a proof-of-concept clinical trial in UP/UPS, in which Brilacidin was administered via enema, showed the treatment’s safety and effectiveness. Half of the patients (six) treated with the compound went into clinical remission and two went into partial remission. Last November, Innovation presented a scientific poster at the inaugu
Subscribe or to access all post and page content.